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  EVIDENCE-BASED ANSWER 
No single study evaluates the effectiveness of osteoporosis screening. However, screening women over the 
age of 65 years—or those between 60–64 years with certain risk factors—is recommended based on available 
evidence. 
First, osteoporosis is common, and its prevalence increases with age (strength of recommendation [SOR]: A—
prospective cohort studies). Second, low bone mineral density predicts fracture risk (SOR: A—prospective 
cohort studies). Finally, the likelihood of osteoporotic fracture is reduced with therapy, such as alendronate 10 
mg/day or risedronate 5 mg/day plus adequate daily calcium and vitamin D (SOR: A—meta-analysis of 
randomized clinical trials). 
Women under 60 years should not be screened (SOR: B—clinical decision rule). There is no evidence to guide 
decisions about screening interval or at what age to stop screening. The long-term risks of newer medications 
used for osteoporosis are unknown. 
  EVIDENCE SUMMARY 
Osteoporosis results in significant morbidity and mortality. In a prospective observational study of women over 
50 years of age, 39.6% had osteopenia and 7.2% had osteoporosis. Osteoporosis was associated with a 
fracture rate 4 times that of normal bone mineral density.1 People with vertebral or hip fractures have a 
reduced relative 5-year survival of 0.81. Excess mortality occurred within the first 6 months following fracture.2 
One prospective cohort study identified 14 independent risk factors for hip fracture.3 The best predictors were 
female gender, age, low weight, and no current estrogen use. For women aged >65 years with no other risks, 
12% to 28% have osteoporosis.4 Multiple risk assessment scales have been studied to identify women aged 
>65 years who are at increased risk; however, none of the scales had good discriminatory performance.5 As a 
result, it is unclear which factors for women under 65 years should trigger screening. 
While multiple technologies exist to measure bone mineral density, dual-energy x-ray absorptiometry (DEXA) 
has been the most validated test for predicting fractures. A meta-analysis of 11 prospective cohort trials 
showed that all sites of bone mineral density measurements correlated with fractures (relative risk [RR], 1.5; 
95% confi-dence interval [CI], 1.4–1.6.). However, DEXA of the femoral neck predicted hip fracture better than 
other measures (RR, 2.6; 95% CI, 2.0–3.5).6 
Additionally, heel ultrasonography was compa-rable with hip DEXA for predicting hip fractures for women over 
65 years (probability of fracture 0.018 vs. 0.023); no studies have compared effec-tiveness for women under 65 
years. 
Multiple therapeutic interventions for osteo-porosis have been demonstrated to reduce frac-tures. Adequate 
calcium and vitamin D appear to prevent fractures. Alendronate and rise-dronate are the only prescription 
medications with evidence showing they prevent hip fractures. 
A meta-analysis of 11 randomized controlled trials including 11,808 women found fewer hip fractures in women 
taking 10 mg/day of alendronate (RR, 0.51; 95% CI, 0.38–0.69; number needed to treat [NNT]=24), and fewer 
vertebral fractures in women taking 5 mg/day of alendronate (RR, 0.52; 95% CI, 0.43–0.65; NNT=72).7 
For these results to apply to screening, study participants must be similar to those identified by general 
population screening. All trials included healthy women with low bone mineral density who were not using 
estrogen, which is similar to women identified by general screening. However, 57% of women recruited for the 
second Fracture Intervention Trial (FIT-II), the largest study, were classified as ineligible. This raises concern 
about the study’s generalizability.8 
The US Preventive Services Task Force did an outcomes estimation of screening effectiveness, combining all 
of the above data (Table).9 Screening 731 women aged 65 to 69 years would prevent 1 hip fracture if those 
with indications for treat-ment took it; screening 248 women would prevent 1 vertebral fracture. As the table 
demonstrates, benefits increase with age. For women under 65 years, benefits are relatively small, unless they 
have other risk factors for osteoporosis. 
 
TABLE 
Hip and vertebral fracture outcomes for osteoporosis screening in 10,000 
postmenopausal women9 
      Age (years)   
Screening outcomes 55–59 65–69 75–79 
Identified with osteoporosis 445 1200 2850 
Hip fracture prevented with 
medication 
2 14 70 
NNS to prevent 1 hip fracture 4338 731 143 
NNT to prevent 1 hip fracture 193 88 41 
Vertebral fractures prevented 7 40 134 
NNS to prevent 1 vertebral 
fracture 
1338 248 75 
NNT to prevent 1 vertebral 
fracture 
60 30 21 
The calculations in this table assume that treatment reduces the risk of vertebral 
fracture by 48%, the risk of hip fracture to 36%, and that 70% of patients will adhere 
to therapy. Table modified from USPSTF report.9 
NNS, number needed to screen for benefit; NNT, number needed to treat for benefit 
  RECOMMENDATIONS FROM OTHERS 
Based on their outcomes model, the US Preventive Services Task Force recommends screening for women 
aged >65 years, and those aged 60 to 65 years who have risk factors.9 In 1998, the National Osteoporosis 
Foundation, in collaboration with many other professional organ-izations, recommended bone mineral density 
test-ing for all women aged >65 years and younger postmenopausal women who have had or are at risk for 
fractures.10 The 2000 Consensus Development Conference from the National Institutes of Health 
recommended an individual-ized approach to screening, stating evidence for universal osteoporosis screening 
is inconclusive.11 The American Association of Clinical Endo-crinologists revised guidelines in 2001 to include 
screening younger postmenopausal women with a body weight <127 lbs or a family history of nontraumatic 
spine or hip fracture.12 
CLINICAL COMMENTARY 
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The value of screening for osteoporosis is a much bigger issue for clinicians since the 
pub-lication of the Women’s Health Initiative study and the consequent decline in the 
number of postmenopausal women using HRT. Evidence for pharmacologic prevention of 
fractures in women who do not meet conventional criteria for osteoporosis is lacking. Data 
on fracture risk with osteoporosis are short-term, and the risks and benefits of long-term 
treatment of women who do have osteoporosis are unknown for all of the treatment 
options. 
The conclusion to focus our screening efforts on women aged 65 years and older, where 
the near-term benefits seem to clearly outweigh the risks, is certainly clinically prudent. 
Irrespective of our wishes, many women in their fifties are getting osteoporosis screening 
at health fairs or shopping malls. Although I do not encourage this age group to be 
screened, when faced with results showing osteoporosis, I do still treat with a 
bisphosphonate, based on the trials noted above. 
R E F E R E N C E S  
1. Siris  ES, Miller  PD, Barrett-Connor  E , et al.  Identification and fracture outcomes 
of undiagnosed low bone mineral density in postmenopausal women: results from 
the National Osteoporosis Risk Assessment.  JAMA 2001;286:2815–2822. 
2. Cooper  C, Atkinson  EJ, Jacobsen  SJ, O’Fallon  WM, Melton  LJ  3rd. Population-
based study of survival after osteo-porotic fractures.  Am J 
Epidemiol 1993;137:1001–1005. 
3. Cummings  SR, Nevitt  MC, Browner  WS , et al.  Risk factors for hip fracture in 
white women. Study of Osteoporotic Fractures Research Group.  N Engl J 
Med 1995;332:767–773. 
4. Cadarette  SM, Jaglal  SB, Kreiger  N, McIsaac  WJ, Darlington  GA, Tu  JV. 
Development and validation of the Osteoporosis Risk Assessment Instrument to 
facilitate selection of women for bone densitometry.  CMAJ 2000;162:1289–1294. 
5. Cadarette  SM, Jaglal  SB, Murray  TM, McIsaac  WJ, Joseph  L, Brown  JP. 
Evaluation of decision rules for referring women for bone densitometry by dual-
energy x-ray absorptiometry.  JAMA 2001;286:57–63. 
6. Marshall  D, Johnell  O, Wedel  H. Meta-analysis of how well measures of bone 
marrow density predict occurrence of osteoporotic fractures.  BMJ 1996;312:1254–
1259. 
7. Cranney  A, Tugwell  P, Adachi  J , et al.  Meta-analyses of therapies for 
postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of 
postmenopausal osteoporosis.  Endocr Rev 2002;23:517–523. 
8. Cummings  SR, Black  DM, Thompson  DE , et al.  Effect of alendronate on risk of 
fracture in women with low bone density but without vertebral fractures: results from 
the Fracture Intervention Trial.  JAMA 1998;280:2077–2082. 
9. Nelson  HD, Helfand  M, Woolf  SH, Allan  JD. Screening for postmenopausal 
osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. 
 Ann Intern Med 2002;137:529–541. 
10.  Physicians Guide to Prevention and Treatment of Osteoporosis. National 
Osteoporosis Foundation. Wash-ington, DC: National Osteoporosis Foundation; 
1999. Available at: www.nof.org/physguide. Accessed on February 24, 2003. 
11. Osteoporosis prevention, diagnosis, and therapy.  NIH Consensus Statement. 
2000; 17:1–45. Available at: http://odp.od.nih.gov/consensus/cons/111/111_state-
ment.htm. Accessed on February 24, 2003. 
12. American Association of Clinical Endocrinologists.  2001 Medical Guidelines for 
Clinical Practice for the Prevention and Management of Postmenopausal 
Osteoporosis. Available at: www.aace.com/clin/guidelines/osteoporosis2001.pdf. 
Accessed on February 24, 2003. 
THE JOURNAL OF FAMILY PRACTICE ©2003 Dowden Health Media 
 
